Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
Mueller Industries Inc: A Key Focus in Mario Gabelli's Latest 13F Filing
Oracle Corp Sees Significant Reduction in Jeremy Grantham's Portfolio
Sumitomo Mitsui Trust Group Inc. Buys 205 Shares of Verona Pharma PLC American Depositary Share $VRNA
Verona Pharma PLC American Depositary Share (VRNA) Projected to Post Earnings on Monday
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks
Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now
What Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck to Buy Verona Pharma for Around $10 Billion
VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
Verona Pharma shares jump with Merck set to acquire company in $10 billion deal
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
Merck to Buy Verona Pharma in $10 Billion Deal
Merck to acquire Verona Pharma for $10 billion
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
Meck looks to soften impact of Keytruda cliff with $10bn tilt for Verona Pharma
Best Momentum Stock to Buy for July 7th
New Strong Buy Stocks for July 7th
Wall Street Analysts Predict a 25.99% Upside in Verona Pharma (VRNA): Here's What You Should Know
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
Here's Why Momentum in Verona Pharma (VRNA) Should Keep going
Verona Pharma: A Blockbuster Franchise In The Making
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
Mizuho's Jared Holz details potential biotech, pharma acquisitions
Verona Pharma Announces June 2025 Investor Conference Participation
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Verona Pharma Announces March 2025 Investor Conference Participation
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)